Abstract
Cardiac microvascular obstruction (MVO) associated with acute myocardial infarction (heart attack) is characterized by partial or complete elimination of perfusion in the myocardial microcirculation. A new catheter-based method (CoFI, Controlled Flow Infusion) has recently been developed to diagnose MVO in the catheterization laboratory during acute therapy of the heart attack. A porcine MVO model demonstrates that CoFI can accurately identify the increased hydraulic resistance of the affected microvascular bed. A benchtop microcirculation model was developed and tuned to reproduce in vivo MVO characteristics. The tuned benchtop model was then used to systematically study the effect of different levels of collateral flow. These experiments showed that measurements obtained in the catheter-based method were adversely affected such that collateral flow may be misinterpreted as MVO. Based on further analysis of the measured data, concepts to mitigate the adverse effects were formulated which allow discrimination between collateral flow and MVO.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Bern, ARTORG Center for Biomedical Engineering Research, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157)
2 University of Bern, ARTORG Center for Biomedical Engineering Research, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157); CorFlow Therapeutics AG, Baar, Switzerland (GRID:grid.5734.5)
3 University of Bern, ARTORG Center for Biomedical Engineering Research, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157); Pennsylvania State University, Department of Biomedical Engineering, University Park, USA (GRID:grid.29857.31) (ISNI:0000 0001 2097 4281)
4 CorFlow Therapeutics AG, Baar, Switzerland (GRID:grid.5734.5)
5 ETH Zurich, Department of Health Science and Technology, Zurich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780); German Heart Center Berlin, Cardiosurgical Research Group, Department of Cardiothoracic and Vascular Surgery, Berlin, Germany (GRID:grid.418209.6) (ISNI:0000 0001 0000 0404)





